These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 35905562)

  • 1. Current evidence on the use of anakinra in COVID-19.
    Khani E; Shahrabi M; Rezaei H; Pourkarim F; Afsharirad H; Solduzian M
    Int Immunopharmacol; 2022 Oct; 111():109075. PubMed ID: 35905562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
    Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
    Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of Anakinra to Prevent Mechanical Ventilation in Severe COVID-19: A Case Series.
    Navarro-Millán I; Sattui SE; Lakhanpal A; Zisa D; Siegel CH; Crow MK
    Arthritis Rheumatol; 2020 Dec; 72(12):1990-1997. PubMed ID: 32602262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High dose subcutaneous Anakinra to treat acute respiratory distress syndrome secondary to cytokine storm syndrome among severely ill COVID-19 patients.
    Iglesias-Julián E; López-Veloso M; de-la-Torre-Ferrera N; Barraza-Vengoechea JC; Delgado-López PD; Colazo-Burlato M; Ubeira-Iglesias M; Montero-Baladía M; Lorenzo-Martín A; Minguito-de-la-Iglesia J; García-Muñoz JP; Sanllorente-Sebastián R; Vicente-González B; Alemán-Alemán A; Buzón-Martín L
    J Autoimmun; 2020 Dec; 115():102537. PubMed ID: 32843231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Inflammatory Cytokines (Interleukin-1 and Interleukin-6) as a Potential Biomarker in the Different Stages of COVID-19 (Mild, Severe, and Critical).
    Ghofrani Nezhad M; Jami G; Kooshkaki O; Chamani S; Naghizadeh A
    J Interferon Cytokine Res; 2023 Apr; 43(4):147-163. PubMed ID: 37062817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunopathogenesis and treatment of cytokine storm in COVID-19.
    Kim JS; Lee JY; Yang JW; Lee KH; Effenberger M; Szpirt W; Kronbichler A; Shin JI
    Theranostics; 2021; 11(1):316-329. PubMed ID: 33391477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous administration of anakinra in children with macrophage activation syndrome.
    Phadke O; Rouster-Stevens K; Giannopoulos H; Chandrakasan S; Prahalad S
    Pediatr Rheumatol Online J; 2021 Jun; 19(1):98. PubMed ID: 34187503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of anakinra in severe COVID-19: A case report.
    Filocamo G; Mangioni D; Tagliabue P; Aliberti S; Costantino G; Minoia F; Bandera A
    Int J Infect Dis; 2020 Jul; 96():607-609. PubMed ID: 32437934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe COVID-19: A case report.
    Franzetti M; Pozzetti U; Carugati M; Pandolfo A; Molteni C; Faccioli P; Castaldo G; Longoni E; Ormas V; Iemoli E; Piconi S
    Int J Infect Dis; 2020 Aug; 97():215-218. PubMed ID: 32422376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An open label trial of anakinra to prevent respiratory failure in COVID-19.
    Kyriazopoulou E; Panagopoulos P; Metallidis S; Dalekos GN; Poulakou G; Gatselis N; Karakike E; Saridaki M; Loli G; Stefos A; Prasianaki D; Georgiadou S; Tsachouridou O; Petrakis V; Tsiakos K; Kosmidou M; Lygoura V; Dareioti M; Milionis H; Papanikolaou IC; Akinosoglou K; Myrodia DM; Gravvani A; Stamou A; Gkavogianni T; Katrini K; Marantos T; Trontzas IP; Syrigos K; Chatzis L; Chatzis S; Vechlidis N; Avgoustou C; Chalvatzis S; Kyprianou M; van der Meer JW; Eugen-Olsen J; Netea MG; Giamarellos-Bourboulis EJ
    Elife; 2021 Mar; 10():. PubMed ID: 33682678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study.
    Bozzi G; Mangioni D; Minoia F; Aliberti S; Grasselli G; Barbetta L; Castelli V; Palomba E; Alagna L; Lombardi A; Ungaro R; Agostoni C; Baldini M; Blasi F; Cesari M; Costantino G; Fracanzani AL; Montano N; Monzani V; Pesenti A; Peyvandi F; Sottocorno M; Muscatello A; Filocamo G; Gori A; Bandera A
    J Allergy Clin Immunol; 2021 Feb; 147(2):561-566.e4. PubMed ID: 33220354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spontaneous NLRP3 inflammasome-driven IL-1-β secretion is induced in severe COVID-19 patients and responds to anakinra treatment.
    Bertoni A; Penco F; Mollica H; Bocca P; Prigione I; Corcione A; Cangelosi D; Schena F; Del Zotto G; Amaro A; Paladino N; Pontali E; Feasi M; Signa S; Bustaffa M; Caorsi R; Palmeri S; Contini P; De Palma R; Pfeffer U; Uva P; Rubartelli A; Gattorno M; Volpi S
    J Allergy Clin Immunol; 2022 Oct; 150(4):796-805. PubMed ID: 35835255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can emapalumab be life saving for refractory, recurrent, and progressive cytokine storm caused by COVID-19, which is resistant to anakinra, tocilizumab, and Janus kinase inhibitors.
    Cure E; Kucuk A; Cure MC
    Indian J Pharmacol; 2021; 53(3):226-228. PubMed ID: 34169908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Proposal for the use of anakinra in acute respiratory distress secondary to COVID-19].
    Muñoz-Jiménez A; Rubio-Romero E; Marenco de la Fuente JL
    Reumatol Clin (Engl Ed); 2021; 17(6):309-312. PubMed ID: 32482538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perspectives on anti-IL-1 inhibitors as potential therapeutic interventions for severe COVID-19.
    Geng J; Wang F; Huang Z; Chen X; Wang Y
    Cytokine; 2021 Jul; 143():155544. PubMed ID: 33926774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of Survival by IL-6 in a Randomized Placebo-Controlled Trial of Anakinra in COVID-19 Cytokine Storm.
    Jackson LE; Khullar N; Beukelman T; Chapleau C; Kamath A; Cron RQ; Chatham WW
    Viruses; 2023 Sep; 15(10):. PubMed ID: 37896812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of anakinra for tocilizumab-refractory severe COVID-19: A single-centre retrospective comparative study.
    de la Calle C; López-Medrano F; Pablos JL; Lora-Tamayo J; Maestro-de la Calle G; Sánchez-Fernández M; Fernández-Ruiz M; Pérez-Jacoiste Asín MA; Caro-Teller JM; García-García R; Catalán M; Martínez-López J; Sevillano Á; Origüen J; Ripoll M; San Juan R; Lalueza A; de Miguel B; Carretero O; Aguilar F; Gómez C; Paz-Artal E; Bueno H; Lumbreras C; Aguado JM
    Int J Infect Dis; 2021 Apr; 105():319-325. PubMed ID: 33592340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial.
    Declercq J; Van Damme KFA; De Leeuw E; Maes B; Bosteels C; Tavernier SJ; De Buyser S; Colman R; Hites M; Verschelden G; Fivez T; Moerman F; Demedts IK; Dauby N; De Schryver N; Govaerts E; Vandecasteele SJ; Van Laethem J; Anguille S; van der Hilst J; Misset B; Slabbynck H; Wittebole X; Liénart F; Legrand C; Buyse M; Stevens D; Bauters F; Seys LJM; Aegerter H; Smole U; Bosteels V; Hoste L; Naesens L; Haerynck F; Vandekerckhove L; Depuydt P; van Braeckel E; Rottey S; Peene I; Van Der Straeten C; Hulstaert F; Lambrecht BN
    Lancet Respir Med; 2021 Dec; 9(12):1427-1438. PubMed ID: 34756178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemophagocytic lymphohistiocytosis in COVID-19: Case reports of a stepwise approach.
    Schnaubelt S; Tihanyi D; Strassl R; Schmidt R; Anders S; Laggner AN; Agis H; Domanovits H
    Medicine (Baltimore); 2021 Mar; 100(12):e25170. PubMed ID: 33761694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A meta analysis on the utility of Anakinra in severe COVID-19 disease.
    Mohamed Hussein AAR; Sayad R; Abdelshafi A; Hammam IA; Kedwany AM; Elkholy SA; Ibrahim IH
    Cytokine; 2023 Sep; 169():156311. PubMed ID: 37536222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.